---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-065634"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:14:26.562375+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sensei reports solnerstotug 14% ORR in PD-(L)1 resistant tumors; Phase 2 planned Q1 2026

## Summary
- 14% ORR (3/21 evaluable) and 62% DCR in PD-(L)1 resistant 'hot' tumors; nearly 3x historical rechallenge response.
- One durable CR in Merkel Cell Carcinoma (42+ weeks) and two PRs (MCC and MSI-H CRC, 12+ and 36+ weeks).
- All patients with tumor shrinkage remain on study, suggesting potential for deepening responses.
- Solnerstotug well tolerated: no DLTs; mild CRS in 4/60 patients (Grade 1 only).
- Phase 2 initiation expected Q1 2026, subject to sufficient capital.

## SEC filing metadata
- accession: 0001193125-25-065634
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312525065634/0001193125-25-065634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312525065634/d831325d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-065634
- JSON: https://secwatch.observer/filing/0001193125-25-065634.json
- Plain text: https://secwatch.observer/filing/0001193125-25-065634.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.